Wednesday, July 8, 2026

Drug profile · INN

carboprost tromethamine

carboprost tromethamine (CARBOPROST TROMETHAMINE) is a prostanoid fp receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — carboprost tromethamine
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.89

Quick answer

carboprost tromethamine (CARBOPROST TROMETHAMINE) is a prostanoid fp receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN carboprost tromethamine
Brand CARBOPROST TROMETHAMINE
Mechanism Prostanoid FP receptor agonist
Target Prostaglandin F2-alpha receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Prostanoid FP receptor agonist

Primary target: Prostaglandin F2-alpha receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. bimatoprost Sensory organs (S01)
  2. dinoprost tromethamine Prostanoid FP receptor agonist
  3. latanoprost Sensory organs (S01)
  4. latanoprostene bunod Prostanoid FP receptor agonist
  5. tafluprost Prostanoid FP receptor agonist
  6. travoprost Sensory organs (S01)

Frequently asked questions

What is carboprost tromethamine?

carboprost tromethamine (CARBOPROST TROMETHAMINE) is a prostanoid fp receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for carboprost tromethamine?

CARBOPROST TROMETHAMINE is a marketed brand name for carboprost tromethamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of carboprost tromethamine?

carboprost tromethamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.